CRISPR Therapeutics AG (CRSP) Cash from Financing Activities (2015 - 2026)

CRISPR Therapeutics AG (CRSP) has 12 years of Cash from Financing Activities data on file, last reported at $591.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 5490.37% year-over-year to $591.9 million; the trailing twelve-month figure through Mar 2026 stood at $1.0 billion (up 2649.46% YoY), and the FY2025 full-year result was $426.0 million, up 28.33% from the prior year.
• Cash from Financing Activities advanced to $591.9 million in Q1 2026, from $116.4 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $591.9 million in Q1 2026 to a low of -$466000.0 in Q2 2024.
• A 5-year average of $85.4 million and a median of $10.6 million in 2022 frame the typical range for Cash from Financing Activities.
• Peak annual rise in Cash from Financing Activities reached 5561.25% in 2024, while the deepest fall reached 102.78% in 2024.
• Tracing CRSP's Cash from Financing Activities over 5 years: stood at $2.5 million in 2022, then jumped by 1471.39% to $38.9 million in 2023, then sank by 56.66% to $16.9 million in 2024, then soared by 589.82% to $116.4 million in 2025, then soared by 408.45% to $591.9 million in 2026.
• Business Quant data shows CRSP's Cash from Financing Activities at $591.9 million in Q1 2026, $116.4 million in Q4 2025, and $296.8 million in Q3 2025.